Ursprung des Netzwerks ersten Grades von Alexander Goubarev
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Cardiorentis AG
 Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland.
5
| Private Company | Pharmaceuticals: Major | 5 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Alexander Goubarev
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| University of St. Gallen | College/University | Graduate Degree | |
| Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree | |
| Johann Wolfgang Goethe-Universität Frankfurt am Main | College/University | Doctorate Degree | |
| University of Zurich | College/University | Graduate Degree | |
Seqens SAS
 Seqens SAS Pharmaceuticals: MajorHealth Technology Seqens SASU engages in pharmaceutical and healthcare industries. The company was founded on April 2, 2003 and is headquartered in Ecully, France. | Pharmaceuticals: Major | Director/Board Member | |
Merck Serono SA
 Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
DiNAQOR AG
 DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Biotechnology | Director of Finance/CFO Chief Executive Officer |
Statistik
International
| Schweiz | 5 |
| Deutschland | 3 |
| Frankreich | 2 |
Sektoral
| Consumer Services | 5 |
| Health Technology | 4 |
Operativ
| Director/Board Member | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 2 |
| Director of Finance/CFO | 2 |
| Graduate Degree | 2 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Alexander Goubarev
- Unternehmensverbindungen
